Atreca, Inc.

If you purchased Atreca, Inc. securities and would like to join the action, please click "Join This Action" below.

We would handle the action on a contingent fee basis, whereby you would not be responsible for out of pocket payment of our legal fees or expenses.



December 26, 2023.


New York, New York—Halper Sadeh LLC, an investor rights law firm, is investigating whether Atreca, Inc.’s (NASDAQ: BCEL) definitive asset purchase agreement with Immunome, Inc. to sell a collection of antibody-related assets and materials is fair to Atreca shareholders. Under the terms of the agreement, Immunome would pay Atreca up to $12.5 million, consisting of a $5.5 million upfront payment and up to $7.0 million in clinical development milestones.


On behalf of Atreca shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.


Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.


Attorney Advertising. Prior results do not guarantee a similar outcome.


Signed pursuant to California Civil Code Section 1633.1, et seq., and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: February 27, 2024